Cyclotox200 mg/vial

Cyclotox is an alkylating agent used, either alone or in combination with other antineoplastic agents, in the treatment of a variety of malignancies and severe autoimmune conditions.

FDA-approved / established uses

• Malignant lymphomas (Hodgkin and non-Hodgkin lymphoma)
• Multiple myeloma
• Leukemias, including chronic lymphocytic leukemia, chronic granulocytic leukemia, acute myelogenous and acute lymphoblastic leukemia
• Mycosis fungoides (advanced disease)
• Neuroblastoma (disseminated disease)
• Adenocarcinoma of the ovary
• Retinoblastoma
• Carcinoma of the breast
• Biopsy-proven minimal change nephrotic syndrome in children who have not responded adequately to corticosteroid therapy

Guideline-supported / specialist off-label uses

• Severe lupus nephritis and other severe manifestations of systemic lupus erythematosus (as part of specialist-directed immunosuppressive protocols)
• ANCA-associated vasculitis (e.g. granulomatosis with polyangiitis, microscopic polyangiitis), typically for remission induction
• Severe, refractory rheumatoid arthritis and other autoimmune/connective tissue diseases unresponsive to standard therapy
• Conditioning regimen prior to hematopoietic stem cell/bone marrow transplantation

Use for autoimmune indications and as part of multi-agent chemotherapy regimens should only be initiated and supervised by a specialist experienced in the use of cytotoxic/immunosuppressive therapy.

Cyclotox is a synthetic nitrogen mustard alkylating agent chemically related to the nitrogen mustards. It is an inactive prodrug that requires hepatic metabolic activation to exert its cytotoxic and immunosuppressive effects.

Cyclotox is used extensively in oncology as part of combination chemotherapy regimens and, at lower doses, as an immunosuppressant in severe autoimmune and rheumatologic disease under specialist supervision.

Alkylating agent (nitrogen mustard analogue); antineoplastic and immunosuppressant agent.

Cyclophosphamide is itself pharmacologically inactive and must be metabolized by hepatic cytochrome P450 enzymes (primarily CYP2B6 and CYP3A4) to the active metabolites 4-hydroxycyclophosphamide and aldophosphamide. These are further converted to phosphoramide mustard, the ultimate cytotoxic alkylating species, and acrolein, a urotoxic byproduct responsible for hemorrhagic cystitis.

Phosphoramide mustard cross-links DNA strands, interfering with DNA replication and transcription, leading to cell death. This action is not phase-specific within the cell cycle, making Cyclophosphamide active against both rapidly dividing tumor cells and, at lower doses, immune cells (T- and B-lymphocytes), which underlies its immunosuppressive effect in autoimmune disease.

Cyclotox tablets are taken orally, generally on an empty stomach; if gastrointestinal upset occurs, may be taken with food. Tablets should be swallowed whole with a full glass of water; adequate fluid intake throughout the day is important to reduce bladder toxicity.

The injectable form must be reconstituted and administered intravenously (or occasionally intramuscularly/intraperitoneally per protocol) by trained healthcare personnel under close medical supervision, with appropriate hydration and, when indicated, mesna co-administration.

Cyclotox has several clinically significant drug interactions:

• Other myelosuppressive drugs/radiation: Additive bone marrow suppression; requires close hematologic monitoring when combined with other chemotherapy agents or radiotherapy.
• Allopurinol: May increase the myelosuppressive effect of Cyclotox; blood counts should be monitored closely if co-administered.
• Digoxin: Cyclotox may reduce gastrointestinal absorption/serum levels of digoxin (particularly tablet formulations); monitor digoxin levels/clinical effect.
• Succinylcholine: Cyclotox inhibits plasma cholinesterase, which can prolong neuromuscular blockade and apnea with succinylcholine; anesthesia providers should be informed of Cyclotox therapy prior to surgery.
• CYP450-modifying drugs: Strong inducers or inhibitors of hepatic CYP2B6/CYP3A4 (e.g. certain antifungals, rifampin, phenobarbital) can alter activation of Cyclotox to its active metabolites, potentially changing efficacy or toxicity.
• Live vaccines: Should generally be avoided during and for a period after Cyclotox therapy due to immunosuppression and risk of disseminated vaccine-strain infection.

Always inform the prescriber of all other medicines, herbal products, and vaccines before starting Cyclotox.

Cyclotox carries serious dose-related toxicities in addition to common adverse effects.

Serious/boxed-warning-level risks

• Myelosuppression: Neutropenia, thrombocytopenia, and anemia, increasing risk of serious infection and bleeding; requires regular blood count monitoring.
• Hemorrhagic cystitis: Caused by the toxic metabolite acrolein; presents as bladder irritation, hematuria, and dysuria. Risk is reduced with adequate hydration and, at higher doses, mesna prophylaxis.
• Cardiotoxicity: Particularly with high-dose regimens (e.g. transplant conditioning); can cause hemorrhagic myocarditis and heart failure.
• Secondary malignancy: Long-term use is associated with increased risk of bladder cancer, myelodysplastic syndrome, and acute leukemia.
• Infertility: Can cause amenorrhea, ovarian failure, azoospermia, and testicular atrophy, which may be irreversible.
• Pulmonary toxicity: Interstitial pneumonitis and pulmonary fibrosis have been reported, especially with prolonged therapy.
• Impaired wound healing and increased infection risk due to immunosuppression.

Common adverse effects

• Nausea and vomiting
• Alopecia (hair loss, usually reversible)
• Anorexia, mucositis/stomatitis
• Diarrhea
• Metallic taste, facial flushing during infusion
• Fatigue
• Syndrome of inappropriate antidiuretic hormone secretion (SIADH) at high doses

Cyclotox is contraindicated in pregnancy. It is a well-established human teratogen and can cause fetal malformations, growth restriction, and fetal death, particularly with first-trimester exposure. Women of childbearing potential should use effective contraception during and for a period after treatment, and pregnancy should be excluded before therapy begins. If pregnancy occurs during treatment, the patient should be informed of the potential risk to the fetus and referred for specialist counseling.

Cyclotox is also contraindicated during breastfeeding, as it is excreted in breast milk and may cause serious adverse effects, including myelosuppression, in the nursing infant. Breastfeeding should be discontinued during treatment.

Cyclotox should be administered only under the supervision of a physician experienced in the use of cytotoxic chemotherapy or immunosuppressive agents.

• Regular monitoring of complete blood counts, renal function, hepatic function, and urinalysis (for hematuria) is required throughout treatment (see Side Effects for details of myelosuppression, hemorrhagic cystitis, and other serious risks).
• Adequate hydration should be maintained, particularly around the time of administration, to reduce bladder toxicity.
• Use with caution in patients with active infection, as immunosuppression may mask or worsen infection.
• Use with caution in patients with impaired renal or hepatic function; dose adjustment may be required.
• Live or live-attenuated vaccines should generally be avoided during therapy (see Interactions).
• Patients should be counseled about the risk of infertility before starting therapy, and fertility preservation options should be discussed where relevant (see Side Effects).
• Delayed wound healing may occur; caution is advised around surgical procedures.

Overdose of Cyclotox can result in severe, potentially life-threatening myelosuppression, hemorrhagic cystitis, cardiotoxicity, and other organ toxicity. There is no specific antidote. Any suspected overdose requires immediate medical attention — contact a physician, hospital emergency department, or poison control center right away. Management is supportive and typically requires hospitalization with close monitoring of blood counts, cardiac and renal function, and treatment of specific complications as they arise.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Reconstituted injectable solutions should be used according to the manufacturer's stability instructions and handled/disposed of as a cytotoxic (hazardous) drug per institutional protocol.

Elderly: Use with caution; age-related decline in renal, hepatic, or bone marrow reserve may increase toxicity risk. Close monitoring and possible dose adjustment are recommended.

Renal impairment: Dose reduction is generally recommended in significant renal impairment, as active metabolites may accumulate and increase toxicity.

Hepatic impairment: Use with caution; dose reduction may be needed in patients with significant hepatic dysfunction, as hepatic activation of Cyclotox may be impaired.

Pediatric: Cyclotox is established for use in children for certain malignancies and for biopsy-proven minimal change nephrotic syndrome unresponsive to corticosteroids, at weight/body-surface-area-based doses determined by a pediatric specialist (see Pediatric Uses).

The injectable powder form of Cyclotox must be reconstituted before use, typically with Sterile Water for Injection, to form a solution as directed by the manufacturer's instructions, and further diluted in a compatible intravenous fluid if required for infusion. Reconstitution and handling should be performed by trained personnel using appropriate cytotoxic drug handling precautions (protective equipment, closed-system transfer where available), and the prepared solution should be used within the stability window stated by the manufacturer and discarded appropriately as hazardous waste if unused.

Alkylating agent; nitrogen mustard analogue; antineoplastic agent; immunosuppressant.

D

Cyclotox is used in children under specialist supervision for certain malignancies (e.g. leukemias, lymphomas, neuroblastoma) as part of established combination chemotherapy protocols, and specifically for biopsy-proven minimal change nephrotic syndrome in children who have not responded adequately to corticosteroid therapy, typically at a weight-based oral dose for a defined course as determined by a pediatric nephrologist or oncologist.

Use in children requires careful attention to growth, fertility risk (which may be more relevant given a child's future reproductive life), and long-term monitoring for secondary malignancy. Safety and efficacy for indications outside established pediatric protocols have not been established, and treatment should only be undertaken by a pediatric specialist experienced with this therapy.